Iradimed Corporation (NASDAQ:IRMD) CFO John Glenn Sells 2,500 Shares

Iradimed Corporation (NASDAQ:IRMD) CFO John Glenn sold 2,500 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $54.18, for a total value of $135,450.00. Following the transaction, the chief financial officer now owns 4,383 shares of the company’s stock, valued at approximately $237,470.94. This represents a 36.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Iradimed Price Performance

NASDAQ IRMD opened at $53.64 on Wednesday. Iradimed Corporation has a 12 month low of $40.18 and a 12 month high of $57.95. The stock has a market capitalization of $679.62 million, a P/E ratio of 36.74 and a beta of 0.82. The firm’s 50-day moving average is $51.79 and its two-hundred day moving average is $47.35.

Iradimed Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, November 25th. Investors of record on Friday, November 15th were given a dividend of $0.15 per share. The ex-dividend date was Friday, November 15th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 1.12%. Iradimed’s payout ratio is currently 41.10%.

Institutional Trading of Iradimed

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB acquired a new stake in shares of Iradimed in the third quarter valued at $126,000. Barclays PLC grew its position in Iradimed by 113.9% in the 3rd quarter. Barclays PLC now owns 23,774 shares of the medical equipment provider’s stock valued at $1,196,000 after acquiring an additional 12,657 shares in the last quarter. Stifel Financial Corp increased its stake in Iradimed by 9.8% during the third quarter. Stifel Financial Corp now owns 24,428 shares of the medical equipment provider’s stock worth $1,229,000 after purchasing an additional 2,174 shares during the period. Jacobs Levy Equity Management Inc. lifted its position in shares of Iradimed by 1.9% during the third quarter. Jacobs Levy Equity Management Inc. now owns 24,779 shares of the medical equipment provider’s stock worth $1,246,000 after purchasing an additional 472 shares in the last quarter. Finally, Walleye Capital LLC purchased a new position in shares of Iradimed in the third quarter valued at approximately $361,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.